TORONTO, Oct. 24, 2022 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or the “Company”), a biopharmaceutical company committed to developing innovative therapeutic solutions for underserved mental health conditions, announced today that it has appointed Edward Smith as the Company’s Chief Financial Officer and Aviva Asnis-Alibozek as Vice President…


Previous articleVariants in 5-HT2A Receptor Gene Alter Psychedelic Pharmacology
Next articleatai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression